The US FDA has approved a high-dose version of Novo Nordisk's injectable drug Wegovy for the treatment of obesity. The drug is available in a dose of 7.2 mg, which is given as three injections of 2.4 mg at a time once a week. In a 72-week clinical trial with 1,407 adult participants without diabetes, patients on the high-dose version lost an average of 20.7% of their body weight, compared to 17.5% on the lower 2.4 mg dose. Novo Nordisk has also applied for approval of a single-dose injectable form of high-dose Wegova, which could be available this year. The high-dose version represents a competitive move against drugs from other manufacturers, such as Eli Lilly, which offer similar weight loss results.